Welcome to our dedicated page for AstraZeneca SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AstraZeneca PLC (AZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. AstraZeneca files under Form 20-F for its annual report and uses Form 6-K to furnish current reports on material developments. These filings cover a broad range of topics, including clinical trial data, regulatory approvals, manufacturing investments, insider share transactions and changes in major shareholdings.
For investors following AstraZeneca’s oncology franchise, 6-K exhibits often reproduce detailed press releases on medicines such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan) and Imfinzi (durvalumab). These documents describe Phase 3 trial designs and endpoints, Breakthrough Therapy Designations, new indications in breast, lung, gastric, endometrial and ovarian cancers, and approvals in key markets. They can help readers understand how specific trials, such as DESTINY-Breast, TROPION, MATTERHORN and others, relate to AstraZeneca’s pipeline and commercial portfolio.
Filings also address Rare Diseases and Respiratory & Immunology, including updates on Koselugo (selumetinib) for neurofibromatosis type 1 and Saphnelo (anifrolumab) for systemic lupus erythematosus. Additional 6-Ks report on large capital projects, such as multi‑billion‑dollar manufacturing investments in Maryland and other US states, and on governance matters like director and senior executive share dealings or notifications of major institutional holdings.
On Stock Titan, these AZN filings are supplemented with AI-powered summaries that explain the key points of each document in plain language. Users can quickly see which filings relate to new indications, safety information, insider transactions (similar to Form 4-style disclosures for US issuers) or strategic investments. Real-time updates from EDGAR ensure that new AstraZeneca 6-Ks and other SEC submissions appear promptly, while AI insights help readers navigate lengthy technical exhibits such as clinical trial descriptions and multi-indication product updates.
AstraZeneca PLC received a TR-1 notification showing The Capital Group Companies, Inc. and its affiliates reported a combined holding of 77,682,857 ordinary shares, representing 4.984560% of voting rights as of 14-Aug-2025. Of that total, 14,351,342 are held as depository receipts (ISIN US0463531089), representing 0.925485% of voting rights. The filing clarifies these shares are owned by client accounts under discretionary management across Capital Group entities, not held for the parent companies' own accounts. The notification supplies the chain of controlled undertakings through which the holdings are managed and is signed by AstraZeneca's Company Secretary on 15 August 2025.
AstraZeneca received a TR-1 notification showing The Capital Group Companies, Inc. and its investment management affiliates crossed the 5% voting threshold in AstraZeneca ordinary shares on 11-Aug-2025. The notification reports a resulting total holding of 5.000629% of voting rights, represented by 77,294,699 underlying voting rights and 14,394,421 depository receipts (ISIN US0463531089) accounting for 0.928264% of voting rights. The filing discloses the full chain of controlled undertakings through which the holdings are held and explains these shares are owned by client accounts under discretionary management by Capital Group entities rather than for Capital Group's own account.
H1 2025 results: Total revenue rose 11% CER to $28.0 bn, led by Oncology (+16%) and BioPharmaceuticals. Product Sales were $26.7 bn (+10%), Alliance Revenue $1.3 bn (+38%). Core EPS reached $4.66 (+17%) and reported EPS $3.46 (+32%) as core operating profit advanced 13%.
Q2 2025: Revenue grew 11% CER to $14.5 bn; core EPS $2.17 (+12%). Gross margin 83%; reported operating margin 24% (core 32%). Key brands outperformed: Tagrisso $3.5 bn (+10%), Imfinzi $2.7 bn (+21%), Enhertu $1.3 bn (+38%) while Soliris (-30%) and Brilinta (-21%) declined.
Capital allocation & strategy: Interim dividend increased 3% to $1.03. AZN acquired cell-therapy firm EsoBiotec for up to $1 bn, signed a $110 m upfront AI-drug-discovery deal with CSPC (milestones up to $5.2 bn) and announced a $50 bn US manufacturing/R&D investment, including a new Virginia drug-substance plant.
R&D momentum: 12 positive Phase III readouts (e.g., baxdrostat BaxHTN, Tagrisso FLAURA2) and 19 approvals. Pipeline breadth reinforced by oncology, CVRM and rare-disease advances.
Guidance reaffirmed: 2025 total revenue to grow high-single-digits and core EPS low-double-digits (CER); FX now seen broadly neutral. Core tax rate 18-22%.
AstraZeneca (AZN) reports that baxdrostat, its orally administered, first-in-class aldosterone synthase inhibitor, met the primary and all secondary endpoints in the pivotal Phase III BaxHTN trial involving 796 patients with uncontrolled or treatment-resistant hypertension. At both 2 mg and 1 mg doses, baxdrostat produced a statistically significant, clinically meaningful reduction in mean seated systolic blood pressure (SBP) at 12 weeks versus placebo when added to standard of care. The compound was “generally well tolerated” and showed a favourable safety profile. Additional endpoints—including diastolic BP, SBP in the resistant-hypertension subgroup, proportion of patients achieving SBP <130 mmHg, and persistence of effect during a randomised withdrawal period—were all achieved.
The BaxHTN study comprises three components: (1) a 12-week double-blind efficacy period, (2) an 8-week withdrawal test of durability, and (3) a 52-week safety follow-up. Data will be shared with regulators worldwide and presented during a late-breaking Hot Line session at the European Society of Cardiology Congress in August 2025.
Hypertension affects 1.3 billion people globally, and roughly half of U.S. patients on multiple drugs remain uncontrolled, underlining the addressable market. By specifically targeting aldosterone—implicated in difficult-to-manage hypertension—baxdrostat introduces a novel mechanism to a therapeutic area with limited innovation in two decades.
AstraZeneca obtained baxdrostat through its February 2023 acquisition of CinCor Pharma; a contingent value right of $10 per CinCor share (≈$0.5 billion) becomes payable upon NDA/MAA submission. Positive Phase III results substantially de-risk that milestone and accelerate the path toward regulatory filings.
AstraZeneca PLC (AZN) has secured European Commission approval for Imfinzi (durvalumab) as the first and only peri-operative immunotherapy for resectable muscle-invasive bladder cancer (MIBC). The label covers combination use with gemcitabine/cisplatin before radical cystectomy and Imfinzi monotherapy after surgery. Approval is based on the NIAGARA Phase III trial, where the Imfinzi regimen produced a 32% reduction in risk of disease progression/recurrence or death (EFS HR 0.68; p<0.0001) and a 25% reduction in overall mortality (OS HR 0.75; p = 0.0106) versus neoadjuvant chemotherapy alone. Two-year event-free and overall survival rates reached 67.8% and 82.2%, respectively, compared with 59.8% and 75.2% for the control arm.
Safety signals were consistent with known profiles; the addition of Imfinzi did not hinder surgical completion. The regimen received the highest “A” grade on ESMO’s Magnitude of Clinical Benefit Scale, highlighting strong clinical value.
Commercially, the EU market represents more than 35,000 treated MIBC patients annually. Given Imfinzi’s prior U.S. approval and ongoing filings in Japan and other regions, the decision materially enlarges the drug’s addressable population and strengthens AstraZeneca’s oncology franchise. Management states Imfinzi is positioned to “transform the standard of care,” setting a new survival benchmark in a setting that has seen few therapeutic advances in decades.